Voyager Therapeutics Inc (NASDAQ:VYGR) has been given an average recommendation of “Buy” by the fourteen research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $32.50.
Several analysts have weighed in on the company. BidaskClub lowered Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. ValuEngine raised Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, July 2nd. Chardan Capital reissued a “hold” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday, June 21st. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Voyager Therapeutics in a report on Thursday, June 7th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $27.00 target price on shares of Voyager Therapeutics in a report on Monday, September 10th.
In related news, Director Glenn Pierce acquired 5,000 shares of Voyager Therapeutics stock in a transaction dated Wednesday, September 12th. The shares were acquired at an average cost of $18.44 per share, for a total transaction of $92,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James A. Geraghty acquired 3,000 shares of Voyager Therapeutics stock in a transaction dated Monday, September 10th. The stock was bought at an average price of $19.39 per share, for a total transaction of $58,170.00. Following the completion of the transaction, the director now directly owns 76,588 shares of the company’s stock, valued at $1,485,041.32. The disclosure for this purchase can be found here. Insiders acquired 11,000 shares of company stock worth $205,300 in the last three months. 33.60% of the stock is owned by corporate insiders.
Several large investors have recently modified their holdings of the company. BB Biotech AG lifted its position in shares of Voyager Therapeutics by 27.1% in the second quarter. BB Biotech AG now owns 2,532,641 shares of the company’s stock valued at $49,488,000 after acquiring an additional 540,000 shares in the last quarter. BlackRock Inc. lifted its position in Voyager Therapeutics by 28.3% during the second quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock worth $36,066,000 after buying an additional 407,677 shares during the period. Farallon Capital Management LLC lifted its position in Voyager Therapeutics by 35.9% during the first quarter. Farallon Capital Management LLC now owns 890,000 shares of the company’s stock worth $16,723,000 after buying an additional 235,188 shares during the period. Millennium Management LLC lifted its position in Voyager Therapeutics by 124.0% during the first quarter. Millennium Management LLC now owns 618,021 shares of the company’s stock worth $11,613,000 after buying an additional 342,148 shares during the period. Finally, Wells Fargo & Company MN lifted its position in Voyager Therapeutics by 15.2% during the second quarter. Wells Fargo & Company MN now owns 450,480 shares of the company’s stock worth $8,802,000 after buying an additional 59,497 shares during the period. Institutional investors and hedge funds own 89.65% of the company’s stock.
VYGR stock traded down $0.33 on Friday, reaching $18.15. 3,816 shares of the company’s stock were exchanged, compared to its average volume of 217,377. Voyager Therapeutics has a twelve month low of $11.54 and a twelve month high of $31.91. The firm has a market capitalization of $584.50 million, a PE ratio of -6.89 and a beta of 2.89.
Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%. equities research analysts anticipate that Voyager Therapeutics will post -3.19 earnings per share for the current year.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.